#BEGIN_DRUGCARD DB03041

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C15H22N2O18P2

# Chemical_IUPAC_Name:
(2R,3R,4R,5S,6R)-6-({[({[(2S,3R,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Udp-Glucuronic Acid

# HET_ID:
UGA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C15H22N2O18P2/c18-5-1-2-17(15(26)16-5)12-9(22)6(19)4(32-12)3-31-36(27,28)35-37(29,30)34-14-10(23)7(20)8(21)11(33-14)13(24)25/h1-2,4,6-12,14,19-23H,3H2,(H,24,25)(H,27,28)(H,29,30)(H,16,18,26)/t4-,6-,7+,8+,9+,10-,11+,12+,14+/m0/s1

# InChI_Key:
InChIKey=HDYANYHVCAPMJV-USQUEEHTSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3041

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
580.2853

# Molecular_Weight_Mono:
580.034284934

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1KWS

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.2

# Predicted_LogS:
-1.5

# Predicted_Water_Solubility:
1.81e+01 g/l

# Primary_Accession_No:
DB03041

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936562

# PubChem_Substance_ID:
46504863

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03177

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[C@H]1[C@H](CO[P@@](O)(=O)O[P@@](O)(=O)O[C@H]2O[C@H]([C@H](O)[C@@H](O)[C@@H]2O)C(O)=O)O[C@H]([C@@H]1O)N1C=CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:51 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L08444

# Drug_Target_1_GenBank_ID_Protein:
295189

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
hasB

# Drug_Target_1_Gene_Sequence:
>1209 bp
ATGAAAATAGCAGTTGCTGGATCAGGATATGTTGGATTATCACTAGGAGTTCTTTTATCA
CTTCAAAACGAAGTCACTATTGTTGATATTCTTCCCTCTAAAGTTGATAAGATTAATAAT
GGCTTATCACCAATTCAAGATGAATATATTGAATATTACTTAAAAAGTAAGCAATTATCT
ATTAAAGCAACTTTAGATAGCAAAGCAGCTTATAAAGAAGCGGAACTGGTCATTATTGCC
ACACCTACAAATTACAACAGTAGAATTAATTATTTTGATACACAGCATGTTGAAACAGTT
ATCAAAGAGGTACTAAGCGTTAATAGCCATGCAACTCTTATCATCAAATCAACAATTCCA
ATAGGTTTCATTACTGAAATGAGACAGAAATTCCAAACTGATCGTATTATCTTCAGCCCT
GAATTTTTAAGAGAATCTAAAGCTTTATATGACAACTTATATCCAAGCCGAATTATTGTT
TCTTGTGAAGAAAACGATTCTCCAAAAGTAAAGGCAGACGCAGAAAAATTTGCACTTTTA
TTAAAGTCTGCAGCTAAAAAAAATAATGTACCAGTACTTATTATGGGAGCTTCAGAAGCT
GAAGCAGTAAAACTATTTGCCAATACTTATTTAGCGTTAAGGGTAGCTTATTTTAATGAG
TTAGACACTTACGCAGAATCGAGAAAATTAAATAGTCACATGATTATTCAAGGAATTTCT
TATGATGATCGAATAGGAATGCATTATAATAACCCATCATTTGGTTATGGAGGTTATTGT
CTACCTAAAGATACGAAGCAATTATTGGCAAATTACAATAATATTCCCCAAACACTAATT
GAAGCTATCGTTTCATCAAATAATGTGCGCAAGTCCTATATTGCTAAGCAAATTATCAAC
GTCTTAAAAGAGCAGGAGTCCCCAGTAAAAGTAGTCGGGGTTTACCGTTTAATTATGAAA
AGTAACTCAGATAACTTTAGAGAAAGTGCTATCAAAGATGTTATTGACATTCTTAAAAGT
AAAGACATTAAGATAATTATTTATGAGCCAATGTTAAACAAACTTGAATCTGAAGATCAA
TCTGTACTTGTAAATGATTTAGAGAATTTCAAGAAACAAGCAAATATTATCGTAACTAAT
CGCTATGATAATGAATTACAAGATGTTAAAAATAAAGTTTACAGTAGAGATATTTTTGGT
AGAGACTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
10841783	Campbell RE, Mosimann SC, van De Rijn I, Tanner ME, Strynadka NC: The first structure of UDP-glucose dehydrogenase reveals the catalytic residues necessary for the two-fold oxidation. Biochemistry. 2000 Jun 13;39(23):7012-23.
8463246	Dougherty BA, van de Rijn I: Molecular characterization of hasB from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose dehydrogenase activity. J Biol Chem. 1993 Apr 5;268(10):7118-24.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3672

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
45484

# Drug_Target_1_Name:
UDP-glucose 6-dehydrogenase

# Drug_Target_1_Number_of_Residues:
402

# Drug_Target_1_PDB_ID:
1DLI

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00984	UDPG_MGDP_dh
PF03720	UDPG_MGDP_dh_C
PF03721	UDPG_MGDP_dh_N

# Drug_Target_1_Protein_Sequence:
>UDP-glucose 6-dehydrogenase
MKIAVAGSGYVGLSLGVLLSLQNEVTIVDILPSKVDKINNGLSPIQDEYIEYYLKSKQLS
IKATLDSKAAYKEAELVIIATPTNYNSRINYFDTQHVETVIKEVLSVNSHATLIIKSTIP
IGFITEMRQKFQTDRIIFSPEFLRESKALYDNLYPSRIIVSCEENDSPKVKADAEKFALL
LKSAAKKNNVPVLIMGASEAEAVKLFANTYLALRVAYFNELDTYAESRKLNSHMIIQGIS
YDDRIGMHYNNPSFGYGGYCLPKDTKQLLANYNNIPQTLIEAIVSSNNVRKSYIAKQIIN
VLKEQESPVKVVGVYRLIMKSNSDNFRESAIKDVIDILKSKDIKIIIYEPMLNKLESEDQ
SVLVNDLENFKKQANIIVTNRYDNELQDVKNKVYSRDIFGRD

# Drug_Target_1_Reaction:
UDP-glucose + 2 NAD+ + H2O = UDP-glucuronate + 2 NADH + 2 H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the formation of UDP-glucuronic acid which is required for capsular hyaluronic acid synthesis

# Drug_Target_1_SwissProt_ID:
P0C0F4

# Drug_Target_1_SwissProt_Name:
UDG_STRPY

# Drug_Target_1_Synonyms:
EC 1.1.1.22
UDP-Glc dehydrogenase
UDP-GlcDH
UDPGDH

# Drug_Target_1_Theoretical_pI:
8.10

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Golgi apparatus
Golgi apparatus membrane
single-pass type II membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
B3GAT3

# Drug_Target_2_GenBank_ID_Gene:
AB009598

# Drug_Target_2_GenBank_ID_Protein:
3892640

# Drug_Target_2_GeneCard_ID:
B3GAT3

# Drug_Target_2_Gene_Name:
B3GAT3

# Drug_Target_2_Gene_Sequence:
>1008 bp
ATGAAGCTGAAGCTGAAGAACGTGTTTCTCGCCTACTTCCTGGTGTCGATCGCCGGCCTC
CTCTACGCGCTGGTACAGCTCGGCCAGCCATGTGACTGCCTTCCTCCCCTGCGGGCAGCA
GCCGAGCAGCTACGGCAGAAGGATCTGAGGATTTCCCAGCTGCAAGCGGAACTCCGACGG
CCACCCCCTGCCCCTGCCCAGCCCCCTGAACCCGAGGCCCTGCCTACTATCTATGTTGTT
ACCCCCACCTATGCCAGGCTGGTACAGAAGGCAGAGCTGGTACGACTGTCCCAGACACTG
AGCCTGGTGCCCCGGCTGCATTGGCTGCTGGTGGAGGATGCTGAGGGTCCCACCCCGCTG
GTCTCAGGGCTGCTGGCTGCCTCTGGCCTCCTCTTCACACACCTGGTGGTCCTCACGCCC
AAAGCCCAGCGGCTTCGGGAGGGCGAGCCTGGCTGGGTTCATCCCCGTGGTGTCGAGCAG
CGGAACAAGGCCCTGGACTGGCTCCGGGGCAGAGGGGGTGCTGTGGGTGGGGAGAAGGAC
CCACCACCACCAGGGACCCAAGGAGTCGTTTACTTTGCTGACGATGACAACACCTACAGC
CGGGAGCTGTCTGAGGAGATGCGCTGGACCCGTGGTGTCTCAGTGTGGCCTGTGGGGCTG
GTGGGCGGCCTGCGATTCGAGGGCCCTCAGGTACAGGACGGCCGGGTAGTGGGCTTCCAC
ACAGCATGGGAGCCCAGCAGGCCCTTCCCTGTGGATATGGCTGGATTTGCCGTGGCCCTG
CCCTTGCTGTTAGATAAGCCCAATGCCCAATTTGATTCCACCGCTCCCCGGGGCCACCTG
GAGAGCAGTCTTCTGAGCCACCTTGTGGATCCCAAGGACCTGGAGCCACGGGCTGCCAAC
TGCACTCGGGTACTGGTGTGGCATACTCGGACAGAGAAGCCCAAGATGAAGCAGGAGGAG
CAGCTGCAGCGGCAGGGCCGGGGCTCAGACCCAGCAATTGAGGTGTGA

# Drug_Target_2_General_Function:
Involved in galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase activity

# Drug_Target_2_General_References:
10526176	Tone Y, Kitagawa H, Imiya K, Oka S, Kawasaki T, Sugahara K: Characterization of recombinant human glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. FEBS Lett. 1999 Oct 15;459(3):415-20.
10842173	Ouzzine M, Gulberti S, Netter P, Magdalou J, Fournel-Gigleux S: Structure/function of the human Ga1beta1,3-glucuronosyltransferase. Dimerization and functional activity are mediated by two crucial cysteine residues. J Biol Chem. 2000 Sep 8;275(36):28254-60.
10946001	Pedersen LC, Tsuchida K, Kitagawa H, Sugahara K, Darden TA, Negishi M: Heparan/chondroitin sulfate biosynthesis. Structure and mechanism of human glucuronyltransferase I. J Biol Chem. 2000 Nov 3;275(44):34580-5.
9506957	Kitagawa H, Tone Y, Tamura J, Neumann KW, Ogawa T, Oka S, Kawasaki T, Sugahara K: Molecular cloning and expression of glucuronyltransferase I involved in the biosynthesis of the glycosaminoglycan-protein linkage region of proteoglycans. J Biol Chem. 1998 Mar 20;273(12):6615-8.
9927678	Herman T, Horvitz HR: Three proteins involved in Caenorhabditis elegans vulval invagination are similar to components of a glycosylation pathway. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):974-9.

# Drug_Target_2_HGNC_ID:
HGNC:923

# Drug_Target_2_HPRD_ID:
07564

# Drug_Target_2_ID:
3408

# Drug_Target_2_Locus:
11q12.3

# Drug_Target_2_Molecular_Weight:
37122

# Drug_Target_2_Name:
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3

# Drug_Target_2_Number_of_Residues:
335

# Drug_Target_2_PDB_ID:
1KWS

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF03360	Glyco_transf_43

# Drug_Target_2_Protein_Sequence:
>Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3
MKLKLKNVFLAYFLVSIAGLLYALVQLGQPCDCLPPLRAAAEQLRQKDLRISQLQAELRR
PPPAPAQPPEPEALPTIYVVTPTYARLVQKAELVRLSQTLSLVPRLHWLLVEDAEGPTPL
VSGLLAASGLLFTHLVVLTPKAQRLREGEPGWVHPRGVEQRNKALDWLRGRGGAVGGEKD
PPPPGTQGVVYFADDDNTYSRELFEEMRWTRGVSVWPVGLVGGLRFEGPQVQDGRVVGFH
TAWEPSRPFPVDMAGFAVALPLLLDKPNAQFDSTAPRGHLESSLLSHLVDPKDLEPRAAN
CTRVLVWHTRTEKPKMKQEEQLQRQGRGSDPAIEV

# Drug_Target_2_Reaction:
UDP-glucuronate + 3-beta-D-galactosyl-4-beta-D-galactosyl-O-beta-D-xylosylprotein = UDP + 3-beta-D-glucuronosyl-3-beta-D-galactosyl-4-beta-D-galactosyl-O- beta-D-xylosylprotein

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Glycosaminoglycans biosynthesis. Involved in forming the linkage tetrasaccharide present in heparan sulfate and chondroitin sulfate. Transfers a glucuronic acid moiety from the uridine diphosphate-glucuronic acid (UDP-GlcUA) to the common linkage region trisaccharide Gal beta 1-3Gal beta 1-4Xyl covalently bound to a Ser residue at the glycosaminylglycan attachment site of proteoglycans. Can also play a role in the biosynthesis of l2/HNK- 1 carbohydrate epitope on glycoproteins. Shows strict specificity for Gal beta1-3Gal beta1-4Xyl, exhibiting negligible incorporation into other galactoside substrates including Galbeta1-3Gal beta1-O- benzyl, Galbeta1-4GlcNAc and Galbeta1-4Glc

# Drug_Target_2_SwissProt_ID:
O94766

# Drug_Target_2_SwissProt_Name:
B3GA3_HUMAN

# Drug_Target_2_Synonyms:
Beta-1,3-glucuronyltransferase 3
EC 2.4.1.135
GlcAT-I
GlcUAT-I
Glucuronosyltransferase-I
UDP-GlcUA:Gal beta-1,3-Gal-R glucuronyltransferase

# Drug_Target_2_Theoretical_pI:
8.47

# Drug_Target_2_Transmembrane_Regions:
8-28

#END_DRUGCARD DB03041
